{"id":"W3092280067","doi":"10.1016/j.clbc.2020.09.014","title":"Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial","year":2020,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Eli Lilly Japan; Chugai Pharmaceutical; PharmaMar; AstraZeneca Australia; Kyowa Hakko Kirin; Astellas Pharma; Eisai; GlaxoSmithKline Australia; Puma Biotechnology; Genentech; Seattle Genetics; Genomic Health; AbbVie; Mount Sylvia Diatomite; Roche; Daiichi-Sankyo; Teva Pharmaceutical Industries; Pfizer Australia; Celgene; Novartis; Merck; GlaxoSmithKline; British Microcirculation Society; Amgen; Ontario Brain Institute; Pfizer; Bayer; AstraZeneca; Eli Lilly and Company","keywords":"Neratinib; Medicine; Breast cancer; Oncology; Hormone receptor; Internal medicine; Stage (stratigraphy); Gynecology; Cancer; Trastuzumab","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001448046,0.0004668491,0.001437518,0.00007315601,0.0001306933,0.00006431602,0.0006124309,0.0004211529,0.002405925],"category_scores_gemma":[0.0009995273,0.0003411882,0.0004670244,0.0008961946,0.0009459919,0.0001607984,0.0002848676,0.00201362,0.00008677054],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004284249,"about_ca_system_score_gemma":0.002001949,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02583043,"about_ca_topic_score_gemma":0.0009648693,"domain_scores_codex":[0.9937054,0.001019348,0.002084308,0.001268388,0.001135318,0.0007872579],"domain_scores_gemma":[0.9949683,0.002265969,0.0005826309,0.0007755082,0.0006133549,0.000794233],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7203633,0.002977092,0.01856165,0.00005415207,0.0007022086,0.0002338271,0.003039515,0.0000964979,0.004264358,0.00003004592,0.04858436,0.201093],"study_design_scores_gemma":[0.2789283,0.004133756,0.7041625,0.001259526,0.0003069247,0.0000163984,0.000360274,0.0007885921,0.00119321,0.00001155647,0.008337277,0.0005016863],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.916825,0.001304469,0.00003795495,0.05824076,0.0007568712,0.002552025,0.01961055,0.00006016671,0.0006122183],"genre_scores_gemma":[0.9858549,0.00201193,0.0001372676,0.004349548,0.006368305,0.0003689174,0.0003214319,0.00008919363,0.0004985709],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6856008,"threshold_uncertainty_score":0.999904,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1250320236614364,"score_gpt":0.4544052343978909,"score_spread":0.3293732107364545,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}